Rating Change
Barclays reiterated its Overweight rating on PTC Therapeutics, Inc. (NASDAQ:PTCT) on August 14, 2026.
reiterateNASDAQ:PTCT
Barclays Reiterates Overweight Rating on PTC Therapeutics, Inc. (PTCT)
Barclays reiterated its Overweight rating on PTC Therapeutics, Inc. (NASDAQ:PTCT) on August 14, 2026.
At publication ·
What changed
PTC Therapeutics, Inc. (NASDAQ:PTCT) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $71.70
- Market capitalization
- $6.1B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on PTC Therapeutics (PTCT) on August 14, 2026, with the stock trading at $71.70 and a market capitalization of $6.1 billion.
Market Context
PTC Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $71.70 with a market capitalization of $6.1B. The stock has gained 46.8% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for PTC Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for PTC Therapeutics, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | Barclays | Overweight | N/A |
| Aug 13, 2026 | Wells Fargo | Overweight | N/A |
| Jul 31, 2026 | Morgan Stanley | Overweight | N/A |
| Jul 31, 2026 | Wells Fargo | Overweight | N/A |
| Jul 20, 2026 | Wells Fargo | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View PTCT Stock Page
Frequently Asked Questions
What does the Overweight rating mean for PTCT?
A rating of Overweight from Barclays reflects the analyst's outlook on PTC Therapeutics, Inc. (NASDAQ:PTCT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PTCT forecast page.